Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.57 |
| ▸ | CLK2 | P49760 | 3/20 | 0.57 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.57 |
| ▸ | FER | P16591 | 2/20 | 0.57 |
| ▸ | CDK2 | P24941 | 2/20 | 0.57 |
| ▸ | MARK3 | P27448 | 2/20 | 0.57 |
| ▸ | FLT4 | P35916 | 2/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.57 |
| ▸ | STK3 | Q13188 | 2/20 | 0.57 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.57 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.57 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.57 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.57 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.57 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28559332 | 0.85 | DYRK1A (0.44) | DYRK1AMAP4K4CLK2MAP4K2AURKB | |
| SCHEMBL29930770 | 0.84 | DYRK1B (0.58) | DYRK1AMAP4K4CLK2MAP4K2AURKB | |
| SCHEMBL29930377 | 0.83 | DYRK1B (0.61) | DYRK1AMAP4K4CLK2MAP4K2AURKB | |
| SCHEMBL29930893 | 0.83 | GSK3B (0.58) | DYRK1AMAP4K4MAP4K2AURKBCLK4 | |
| SCHEMBL29930540 | 0.82 | DYRK1B (0.62) | DYRK1AMAP4K4CLK2MAP4K2AURKB | |
| SCHEMBL28549696 | 0.81 | PIM1 (0.55) | DYRK1AMAP4K4CLK2MAP4K2AURKB | |
| SCHEMBL28562998 | 0.80 | DYRK1B (0.61) | DYRK1ADYRK1BSYKPDE1APDE1B | |
| SCHEMBL38652158 | 0.80 | AURKA (0.48) | DYRK1AMAP4K4CLK2MAP4K2AURKB | |
| SCHEMBL28553148 | 0.80 | DYRK1B (0.56) | DYRK1AMAP4K4CLK2MAP4K2AURKB | |
| SCHEMBL1592857 | 0.80 | ALDH1A1 (0.46) | DYRK1AMAP4K4CLK2MAP4K2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-23 | — | — | US | claimed |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-02 | — | — | US | claimed |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2009-12-17 | — | — | US | claimed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | claimed |
| EP-1912966-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB, S.A. (BE) | 2008-04-23 | — | — | EP | claimed |
| EP-1891042-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB Pharma, S.A. (BE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006128692-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | claimed |
| WO-2006128693-A2 | 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | claimed |
| WO-2022235097-A1 | PHARMACEUTICAL COMPOSITION CONTAINING NOVEL PYRAZOLO[3,4-B]PYRIDINE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE INCLUDING OBESITY AND DIABETES MELLITUS OR NONALCOHOLIC STEATOHEPATITIS | 한국화학연구원 | 2022-11-10 | — | — | WO | disclosed |
| CN-112724134-B | Azaindazole bipyridine derivative myeloid cell proliferation inhibitor, preparation method and application thereof in pharmacy | 复旦大学 | 2022-04-01 | — | — | CN | disclosed |
| CN-112724134-A | Azaindazole bipyridine derivative myeloid cell proliferation inhibitor, preparation method and application thereof in pharmacy | 复旦大学 | 2021-04-30 | — | — | CN | disclosed |
| US-8586623-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-11-19 | — | — | US | disclosed |
| US-8586623-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-11-19 | — | — | US | disclosed |
| EP-1891042-B1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA SA (BE) | 2013-10-02 | — | — | EP | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
| EP-1912966-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB, S.A. (BE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1891042-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB Pharma, S.A. (BE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128693-A2 | 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006128692-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | DYRK1A 3416/4885MAP4K4 3354/4885CLK2 2737/4885 |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | DYRK1A 3416/4885MAP4K4 3354/4885CLK2 2737/4885 |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | DYRK1A 3416/4885MAP4K4 3354/4885CLK2 2737/4885 |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | OPRD1, PPOX, CYP2D6 | DYRK1A 2950/4885MAP4K4 3295/4885CLK2 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.